Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Cost-effectiveness of Nucleic Acid Amplification Testing to Guide Treatment for Vaginitis: A Decision-Modeling Analysis

Cost-effectiveness of Nucleic Acid Amplification Testing to Guide Treatment for Vaginitis: A Decision-modeling Analysis

Authors: Li Y, Feringa BL, Devlin JJ.

Citation: Diagn Microbiol Infect Dis. 2020 Jun 25;98(2):115119. doi: 10.1016/j.diagmicrobio.2020.115119. Online ahead of print.

Specialties: Women's Health, OB/GYN, Infectious disease

Download key summary

Related content

Vaginitis Polymerase Chain Reaction (PCR) Testing and Occurrence of Mixed Infections: Results From a Large US Clinical Laboratory
Publication
Trichomonas vaginalis detection in urogenital specimens from symptomatic and asymptomatic men and women using the cobas TV/MG test
Test FAQ
SureSwab® Advanced Vaginitis, TMA
Test FAQ
SureSwab® Advanced Candida Vaginitis (CV), TMA
Test FAQ
SureSwab® Advanced Vaginitis Plus, TMA

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.